Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$2.51 +6.4%	$7.07	$2.33 ▼ $39.95	$1.92M	0.88	66,885 shs	61,273 shs
CYTR LadRx		$0.09	$0.05 ▼ $0.86	$4.14M	N/A	99,706 shs	4,000 shs
PMCBD PharmaCyte Biotech	$1.01 +12.2%	$1.01	$5.56 ▼ $55.50	$1.69M	0.27	8,831 shs	275,511 shs
SRNEQ Sorrento Therapeutics	$0.00 -67.2%	$0.00	$0.00 ▼ $0.42	$1.16M	2.25	511,766 shs	1.26 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	-10.94%	-8.88%	-74.49%	-74.18%	-92.21%
CYTR LadRx	0.00%	0.00%	0.00%	0.00%	0.00%
PMCBD PharmaCyte Biotech	0.00%	+8.42%	-12.63%	-15.10%	-52.13%
SRNEQ Sorrento Therapeutics	0.00%	+40.00%	+50.00%	0.00%	-76.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIM AIM ImmunoTech	1.3823 of 5 stars	3.5	0.0	0.0	0.0	2.0	0.0	0.0
CYTR LadRx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PMCBD PharmaCyte Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SRNEQ Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIM AIM ImmunoTech	3.00	Buy	$275.00	10,856.18% Upside
CYTR LadRx	0.00	N/A	N/A	N/A
PMCBD PharmaCyte Biotech	0.00	N/A	N/A	N/A
SRNEQ Sorrento Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIM AIM ImmunoTech	$121K	15.85	N/A	N/A	$0.20 per share	12.55
CYTR LadRx	N/A	N/A	N/A	N/A	N/A	N/A
PMCBD PharmaCyte Biotech	N/A	N/A	N/A	N/A	N/A	N/A
SRNEQ Sorrento Therapeutics	$62.84M	0.02	N/A	N/A	($0.05) per share	-0.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIM AIM ImmunoTech	-$28.96M	-$24.68	N/A	N/A	N/A	-12,594.21%	-421.73%	-147.54%	N/A
CYTR LadRx	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PMCBD PharmaCyte Biotech	-$3.83M	N/A	0.00	∞	N/A	N/A	-49.09%	-43.39%	N/A
SRNEQ Sorrento Therapeutics	-$572.84M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A	N/A
CYTR LadRx	N/A	N/A	N/A	N/A	N/A
PMCBD PharmaCyte Biotech	N/A	N/A	N/A	N/A	N/A
SRNEQ Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIM AIM ImmunoTech	0.05	0.75	0.75
CYTR LadRx	N/A	N/A	N/A
PMCBD PharmaCyte Biotech	N/A	4.90	4.90
SRNEQ Sorrento Therapeutics	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIM AIM ImmunoTech	12.02%
CYTR LadRx	N/A
PMCBD PharmaCyte Biotech	0.02%
SRNEQ Sorrento Therapeutics	0.02%

Insider Ownership

Company	Insider Ownership
AIM AIM ImmunoTech	0.02%
CYTR LadRx	N/A
PMCBD PharmaCyte Biotech	N/A
SRNEQ Sorrento Therapeutics	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIM AIM ImmunoTech	20	764,000	68.74 million	Not Optionable
CYTR LadRx	N/A	45.04 million	N/A	Not Optionable
PMCBD PharmaCyte Biotech	N/A	1.67 million	N/A	Not Optionable
SRNEQ Sorrento Therapeutics	800	551.28 million	536.95 million	Not Optionable

PMCBD, CYTR, AIM, and SRNEQ Headlines

Recent News About These Companies

Sorrento Therapeutics Restructuring Chief Hosted Party for Judges Who Later Oversaw Its Liquidation

September 3, 2024 | wsj.com

Sorrento, Naples, Italy Weather Conditionsstar_ratehome

August 28, 2024 | wunderground.comW

Sorrento, British Columbia, Canada 10-Day Weather Forecaststar_ratehome

August 26, 2024 | wunderground.comW

Sorrento Announces New Board Member

August 22, 2024 | br.advfn.com

Sorrento wins DoJ’s venue-based challenge to bankruptcy filing

March 12, 2024 | msn.com

Sorrento’s Bankruptcy Venue Action Is ‘Unprecedented,’ DOJ Says

March 9, 2024 | news.bloomberglaw.comN

Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute

February 29, 2024 | reuters.com

Virpax reaches deal to settle litigation with Sorrento Therapeutics, Scilex Pharmaceuticals

February 27, 2024 | bizjournals.com

Sorrento Therapeutics Stock (OTC:SRNEQ) Dividends: History, Yield and Dates

February 22, 2024 | benzinga.com

Sorrento faked venue in bankruptcy filing, Justice Department says

February 21, 2024 | msn.com

Sorrento Therapeutics Inc (SRNEQ) Earnings Dates & Reports

November 18, 2023 | investing.com

Scilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate ...

October 7, 2023 | bakersfield.comB

Scilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock Price

October 7, 2023 | finance.yahoo.com

Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted ...

October 4, 2023 | bakersfield.comB

Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company

October 3, 2023 | finance.yahoo.com

Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.

September 21, 2023 | finance.yahoo.com

Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)

September 14, 2023 | finance.yahoo.com

Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder

September 13, 2023 | finance.yahoo.com

Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19

September 12, 2023 | finance.yahoo.com

Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available Information

September 11, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PMCBD, CYTR, AIM, and SRNEQ Company Descriptions

AIM ImmunoTech NYSE:AIM

$2.51 +0.15 (+6.36%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 -0.01 (-0.60%)

As of 06:43 PM Eastern

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

LadRx NASDAQ:CYTR

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

PharmaCyte Biotech OTCMKTS:PMCBD

$1.01 +0.11 (+12.23%)

As of 08/18/2025

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

Sorrento Therapeutics OTCMKTS:SRNEQ

$0.0021 0.00 (-67.19%)

As of 08/15/2025

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time